<table id="_RefID0EQMAG" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3. Drug(s) Affecting Pharmacokinetics of CRESEMBA</caption>
<col width="20%"></col>
<col width="26%"></col>
<col width="54%"></col>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">
<sup>a </sup>400 mg of lopinavir in combination with 100 mg of ritonavir.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top"></td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Recommendation</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Comments</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ketoconazole</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Contraindicate coadministration of all potent CYP3A4 inhibitors</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>There is more than a 5-fold increase in exposure of isavuconazole upon coadministration with ketoconazole <br/>
<content stylecode="italics">[see <linkhtml href="#ID_4df688e1-3372-46f1-84fe-26bb9c068e2e">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_99c5510a-23ee-483b-a9aa-cb3f925d04cd">12.3</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Lopinavir/ritonavir<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Caution is advised when CRESEMBA is coadministered with lopinavir/ritonavir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>There is a 96% increase in exposure of isavuconazole when coadministered with lopinavir/ritonavir <br/>
<content stylecode="italics">[see <linkhtml href="#ID_4df688e1-3372-46f1-84fe-26bb9c068e2e">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_99c5510a-23ee-483b-a9aa-cb3f925d04cd">12.3</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Rifampin</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Contraindicate coadministration of all potent CYP3A4 inducers</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>There is a 97% decrease in exposure of isavuconazole upon coadministration with rifampin<br/>
<content stylecode="italics">[see <linkhtml href="#ID_4df688e1-3372-46f1-84fe-26bb9c068e2e">Clinical Pharmacology</linkhtml> (<linkhtml href="#ID_99c5510a-23ee-483b-a9aa-cb3f925d04cd">12.3</linkhtml>)]</content>.</paragraph>
</td>
</tr>
</tbody>
</table>